168427-74-5

Basic information

• Product Name: 2'-O-MOE-ADENOSINE
• Synonyms: 2'-O-MOE-ADENOSINE;2'-O-(2-METHOXYETHYL)ADENOSINE;Adenosine, 2'-O-(2-Methoxyethyl)-;(2R,3R,4R,5R)-5-(6-AMino-9H-purin-9-yl)-2-(hydroxyMethyl)-4-(2-Methoxyethoxy)tetrahydrofuran-3-ol;(2R,3R,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(hydroxy-methyl)-4-(2-methoxyethoxy)tetrahydrofuran-3-o;(2R,3R,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(hydroxy-methyl)-4-(2-methoxyethoxy)tetrahydrofuran-;2'-O-MOE-A;2'-O-Methoxyethyl-adenosine
• CAS NO: 168427-74-5
• Molecular Formula: C₁₃H₁₉N₅O₅
• Molecular Weight: 325.32
• EINECS: 500-100-4
• Product Categories: Bases & Related Reagents;Carbohydrates & Derivatives;Heterocycles;Nucleotides
• Mol File: 168427-74-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 638.954 °C at 760 mmHg
• Flash Point: 340.227 °C
• Appearance: /
• Density: 1.701 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.72
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 13.12±0.70(Predicted)
• CAS DataBase Reference: 2'-O-MOE-ADENOSINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-O-MOE-ADENOSINE(168427-74-5)
• EPA Substance Registry System: 2'-O-MOE-ADENOSINE(168427-74-5)

Safety Data

• Hazardous Substances Data: 168427-74-5(Hazardous Substances Data)

Usage

Uses

A adenosine derivative as building blocks for cross-linking oligonucleotides.

InChI:InChI=1/C13H19N5O5/c1-21-2-3-22-10-9(20)7(4-19)23-13(10)18-6-17-8-11(14)15-5-16-12(8)18/h5-7,9-10,13,19-20H,2-4H2,1H3,(H2,14,15,16)/t7-,9+,10+,13-/m1/s1

Upstream product

• 6482-24-2 2-Bromoethyl methyl ether 
• 58-61-7 adenosine 
• 17178-10-8 2-methoxy-ethyl p-toluenesulfonyloxy ester 
• 16427-44-4 2-methoxyethyl methanesulfonate 
• 168427-72-3 9-<3',5'-Bis-O-(2,4-dichlorobenzyl)-2'-O-(2-methoxyethyl)-β-D-ribofuranosyl>-6-methoxy-9H-purin 
• 168427-69-8 2-O-Acetyl-3',5'-bis-O-(2,4-dichlorobenzyl)inosin 
• 168427-70-1 9-<2'-O-Acetyl-3',5'-bis-O-(2,4-dichlorobenzyl)-β-D-ribofuranosyl>-6-chloro-9H-purin 
• 168427-71-2 9-<3',5'-Bis-O-(2,4-dichlorobenzyl)-β-D-ribofuranosyl>-6-methoxy-9H-purin 
• 163759-40-8 methyl 2,3,5-tris-O-(2,4-dichlorobenzyl)-β-D-ribofuranoside 
• 163759-42-0 Methyl-2-O-acetyl-3,5-bis-O-(2,4-dichlorobenzyl)-α-D-ribofuranosid 
• 168427-35-8 (3R,4S,5R)-4-((2,4-dichlorobenzyl)oxy)-5-(((2,4-dichlorobenzyl)oxy)methyl)-2-methoxytetrahydrofuran-3-ol 
• 50-69-1 D-ribose 
• 440327-54-8 3',5'-di-O-levulinyl-2'-O-(2-methoxyethyl)adenosine 
• 4296-15-5 2-iodo-1-methoxyethane 

Downstream Products

• 251647-48-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N6-benzoyladenosine 
• 333335-93-6 2'-O-methoxyethyl- N⁶-benzoyl -adenosine 

Relevant articles and documents

Synthesis and cellular activity of stereochemically-pure 2′-O-(2-methoxyethyl)-phosphorothioate oligonucleotides

Stereochemically-pure 2′-O-(2-methoxyethyl)-phosphorothioate (PS-MOE) oligonucleotides were synthesized from new chiral oxazaphospholidine-containing nucleosides. Thermal stability studies showed that the incorporation of Rp-PS linkages increased RNA-binding affinity. In cells, a full Rp-PS-MOE splice-switching oligonucleotide targeting part of the ferrochelatase gene was more potent than its Sp-PS counterpart, but of similar potency to the stereorandom PS-parent sequence.

2 the [...] -O-(2- armor oxygen ethyl) adenosine and 2 the [...] -O-(2- armor oxygen ethyl) guanosine and its derivatives preparation and its purification method

The invention discloses 2'-O-(2-methoxyethyl)adenosine and 2'-O-(2-methoxyethyl)guanosine, preparation of derivatives thereof and purifying methods thereof. The invention provides a preparation method of a compound shown as a formula A. The method compris

Phosphorus containing cyclic nucleotides

The invention relates to a compound of formula (I) Wherein: B is adenine, guanine or hypoxanthine Z is hydrogen or a negative charge R is —[CH2CH(R1)—O]n—R2, —CH2CH2X, in which R1is hydrogen or (C1-C6) alkyl R2is hydrogen or (C1-C6) alkyl n is a number from 1 to 6 X is OH, F, NR3R4 R3and R4are independently from each other hydrogen or (C1-C6) alkyl and to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.